Literature DB >> 19934316

Global changes in processing of mRNA 3' untranslated regions characterize clinically distinct cancer subtypes.

Priyam Singh1, Travis L Alley, Sarah M Wright, Sonya Kamdar, William Schott, Robert Y Wilpan, Kevin D Mills, Joel H Graber.   

Abstract

Molecular cancer diagnostics are an important clinical advance in cancer management, but new methods are still needed. In this context, gene expression signatures obtained by microarray represent a useful molecular diagnostic. Here, we describe novel probe-level microarray analyses that reveal connections between mRNA processing and neoplasia in multiple tumor types, with diagnostic potential. We now show that characteristic differences in mRNA processing, primarily in the 3'-untranslated region, define molecular signatures that can distinguish similar tumor subtypes with different survival characteristics, with at least 74% accuracy. Using a mouse model of B-cell leukemia/lymphoma, we find that differences in transcript isoform abundance are likely due to both alternative polyadenylation (APA) and differential degradation. While truncation of the 3'-UTR is the most common observed pattern, genes with elongated transcripts were also observed, and distinct groups of affected genes are found in related but distinct tumor types. Genes with elongated transcripts are overrepresented in ontology categories related to cell-cell adhesion and morphology. Analysis of microarray data from human primary tumor samples revealed similar phenomena. Western blot analysis of selected proteins confirms that changes in the 3'-UTR can correlate with changes in protein expression. Our work suggests that alternative mRNA processing, particularly APA, can be a powerful molecular biomarker with prognostic potential. Finally, these findings provide insights into the molecular mechanisms of gene deregulation in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19934316      PMCID: PMC2794997          DOI: 10.1158/0008-5472.CAN-09-2236

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  The BARD1-CstF-50 interaction links mRNA 3' end formation to DNA damage and tumor suppression.

Authors:  F E Kleiman; J L Manley
Journal:  Cell       Date:  2001-03-09       Impact factor: 41.582

Review 2.  Post-transcriptional regulation in cancer.

Authors:  Yann Audic; Rebecca S Hartley
Journal:  Biol Cell       Date:  2004-09       Impact factor: 4.458

3.  BRCA1/BARD1 inhibition of mRNA 3' processing involves targeted degradation of RNA polymerase II.

Authors:  Frida E Kleiman; Foon Wu-Baer; Danae Fonseca; Syuzo Kaneko; Richard Baer; James L Manley
Journal:  Genes Dev       Date:  2005-05-15       Impact factor: 11.361

Review 4.  Gene expression omnibus: microarray data storage, submission, retrieval, and analysis.

Authors:  Tanya Barrett; Ron Edgar
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

5.  Proliferating cells express mRNAs with shortened 3' untranslated regions and fewer microRNA target sites.

Authors:  Rickard Sandberg; Joel R Neilson; Arup Sarma; Phillip A Sharp; Christopher B Burge
Journal:  Science       Date:  2008-06-20       Impact factor: 47.728

6.  The nonhomologous end joining factor Artemis suppresses multi-tissue tumor formation and prevents loss of heterozygosity.

Authors:  Y Woo; S M Wright; S A Maas; T L Alley; L B Caddle; S Kamdar; J Affourtit; O Foreman; E C Akeson; D Shaffer; R T Bronson; H C Morse; D Roopenian; K D Mills
Journal:  Oncogene       Date:  2007-03-26       Impact factor: 9.867

Review 7.  Stratification of acute myeloid leukemia based on gene expression profiles.

Authors:  Hiroyuki Mano
Journal:  Int J Hematol       Date:  2004-12       Impact factor: 2.490

8.  The 160-kD subunit of human cleavage-polyadenylation specificity factor coordinates pre-mRNA 3'-end formation.

Authors:  K G Murthy; J L Manley
Journal:  Genes Dev       Date:  1995-11-01       Impact factor: 11.361

9.  MicroRNA expression in lymphocyte development and malignancy.

Authors:  C H Lawrie; N J Saunders; S Soneji; S Palazzo; H M Dunlop; C D O Cooper; P J Brown; X Troussard; H Mossafa; T Enver; F Pezzella; J Boultwood; J S Wainscoat; C S R Hatton
Journal:  Leukemia       Date:  2008-01-10       Impact factor: 11.528

10.  Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer.

Authors:  Meng Li; Curt Balch; John S Montgomery; Mikyoung Jeong; Jae Hoon Chung; Pearlly Yan; Tim H M Huang; Sun Kim; Kenneth P Nephew
Journal:  BMC Med Genomics       Date:  2009-06-08       Impact factor: 3.063

View more
  82 in total

Review 1.  Alternative mRNA polyadenylation in eukaryotes: an effective regulator of gene expression.

Authors:  Carol S Lutz; Alexandra Moreira
Journal:  Wiley Interdiscip Rev RNA       Date:  2011 Jan-Feb       Impact factor: 9.957

Review 2.  To polyadenylate or to deadenylate: that is the question.

Authors:  Xiaokan Zhang; Anders Virtanen; Frida E Kleiman
Journal:  Cell Cycle       Date:  2010-11-15       Impact factor: 4.534

Review 3.  Signals for pre-mRNA cleavage and polyadenylation.

Authors:  Bin Tian; Joel H Graber
Journal:  Wiley Interdiscip Rev RNA       Date:  2011-10-19       Impact factor: 9.957

4.  Transcriptome dynamics through alternative polyadenylation in developmental and environmental responses in plants revealed by deep sequencing.

Authors:  Yingjia Shen; R C Venu; Kan Nobuta; Xiaohui Wu; Varun Notibala; Caghan Demirci; Blake C Meyers; Guo-Liang Wang; Guoli Ji; Qingshun Q Li
Journal:  Genome Res       Date:  2011-08-03       Impact factor: 9.043

5.  RNA polymerase II kinetics in polo polyadenylation signal selection.

Authors:  Pedro A B Pinto; Telmo Henriques; Marta O Freitas; Torcato Martins; Rita G Domingues; Paulina S Wyrzykowska; Paula A Coelho; Alexandre M Carmo; Claudio E Sunkel; Nicholas J Proudfoot; Alexandra Moreira
Journal:  EMBO J       Date:  2011-05-20       Impact factor: 11.598

6.  Cleavage factor 25 deregulation contributes to pulmonary fibrosis through alternative polyadenylation.

Authors:  Tingting Weng; Junsuk Ko; Chioniso P Masamha; Zheng Xia; Yu Xiang; Ning-Yuan Chen; Jose G Molina; Scott Collum; Tinne C Mertens; Fayong Luo; Kemly Philip; Jonathan Davies; Jingjing Huang; Cory Wilson; Rajarajan A Thandavarayan; Brian A Bruckner; Soma Sk Jyothula; Kelly A Volcik; Lei Li; Leng Han; Wei Li; Shervin Assassi; Harry Karmouty-Quintana; Eric J Wagner; Michael R Blackburn
Journal:  J Clin Invest       Date:  2019-02-28       Impact factor: 14.808

7.  Alternative polyadenylation in glioblastoma multiforme and changes in predicted RNA binding protein profiles.

Authors:  Jiaofang Shao; Jing Zhang; Zengming Zhang; Huawei Jiang; Xiaoyan Lou; Bingding Huang; Gregory Foltz; Qing Lan; Qiang Huang; Biaoyang Lin
Journal:  OMICS       Date:  2013-02-19

Review 8.  Poly(A) binding proteins: are they all created equal?

Authors:  Dixie J Goss; Frida Esther Kleiman
Journal:  Wiley Interdiscip Rev RNA       Date:  2012-12-13       Impact factor: 9.957

Review 9.  Dysregulation of the basal RNA polymerase transcription apparatus in cancer.

Authors:  Megan J Bywater; Richard B Pearson; Grant A McArthur; Ross D Hannan
Journal:  Nat Rev Cancer       Date:  2013-05       Impact factor: 60.716

10.  Cleavage and polyadenylation specificity factor 1 (CPSF1) regulates alternative splicing of interleukin 7 receptor (IL7R) exon 6.

Authors:  Irina Evsyukova; Shelton S Bradrick; Simon G Gregory; Mariano A Garcia-Blanco
Journal:  RNA       Date:  2012-11-14       Impact factor: 4.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.